Cognitive Decline in AD

Alzheimer Disease Clinical Trial

Official title:

A Cohort Study of Cognitive Decline in Alzheimer Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03946930
• Other study ID #: 2018.274
• Status: Recruiting
• Start date: December 13, 2018
• Est. completion date: December 31, 2025

Study information

• Verified date: October 2022
• Source: Chinese University of Hong Kong
• Contact: Timothy Kwok, MD
• Phone: +852 35053145
• Email: tkwok[@]cuhk.edu.hk
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

There is lack of information on the risk factors of accelerated cognitive decline in older people with Alzheimer disease (AD). The extent of neurodegeneration and white matter disease has been reported to be important factors. In addition there may be biomarkers e.g. inflammatory cytokines that can contribute to cognitive decline. The impact of care arrangement and physical activity may also be important. Insulin signaling is impaired in Alzheimer disease (AD).

We therefore propose to perform a cohort study of older people with AD. This will be based on an on-going AD registry which was designed to identify genetic biomarkers for AD. Detailed neurocognitive tests and lifestyle information are available. In addition, volumetric MRI brain scans were performed in all AD subjects. The hypothesis is that MRI brain volumes, serum biomarkers, physical activity, physical functioning are independently associated with cognitive decline in older people with AD. The objective is to identify risk factors of accelerated cognitive decline so that preventive measures can be designed to delay dependency in AD.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 500
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years to 92 Years

Eligibility

Inclusion Criteria:

• Sufficient Cantonese competency for cognitive test

• Clinical diagnosis of AD

• FAST test staging 3-5

Exclusion Criteria:

• Subjects who refuse blood taking procedure

• No reliable family caregiver informant (person contact at least once a month)

Related Conditions & MeSH terms

• Alzheimer Disease
• Cognitive Dysfunction

Locations

Country	Name	City	State
Hong Kong	The Chinese University of Hong Kon	Hong Kong

Sponsors (1)

Lead Sponsor	Collaborator
Chinese University of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Alzheimer's Disease Assessment Scale-cognitive subscale ADAS-COG	Cognitive assessment for dementia	24-Months